help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on May 6, 2004
Molecular Endocrinology, doi:10.1210/me.2004-0065
Molecular Endocrinology Vol. 0, No. 2004 200400651-
doi:10.1210/me.2004-0065
Copyright © 2004 by the Endocrine Society.
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
18/8/2011    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Powzaniuk, M.
Right arrow Articles by Bai, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Powzaniuk, M.
Right arrow Articles by Bai, C.

Submitted on February 13, 2004
Accepted on April 29, 2004

The LATS2/KPM Tumor Suppressor is a Negative Regulator of the Androgen Receptor

Mark Powzaniuk, Sheila McElwee-Witmer, Robert L. Vogel, Tadashi Hayami, Su Jane Rutledge, Fang Chen, Shun-ichi Harada, Azriel Schmidt, Gideon A. Rodan, Leonard P. Freedman, and Chang Bai*

Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, PA 19486-0004

* To whom correspondence should be addressed. E-mail: chang bai{at}merck.com.

The androgen receptor (AR) is a member of the steroid receptor superfamily that plays critical roles in the development and maintenance of the male reproductive system and in prostate cancer. Actions of AR are controlled by interaction with several classes of coregulators. In this study, we have identified LATS2/KPM as a novel AR-interacting protein. Human LATS1 and LATS2 are tumor suppressors that are homologues of Drosophila warts/lats. The interaction surface of LATS2 is mapped to the central region of the protein while the AR LBD is sufficient for this interaction. LATS2 functions as a modulator of AR by inhibiting androgen-regulated gene expression. The mechanism of LATS2 mediated repression of AR activity appears to involve the inhibition of AR NH2- and COOH-terminal (N/C) interaction. Chromatin immunoprecipitation assays in human prostate carcinoma cells reveal that LATS2 and AR are present in the protein complex that binds at the promoter and enhancer regions of prostate specific antigen (PSA), and overexpression of LATS2 results in a reduction in androgen induced expression of endogenous PSA mRNA. Immunohistochemistry shows that LATS2 and AR are localized within the prostate epithelium and that LATS2 expression is lower in human prostate tumor samples than in normal prostate. The results suggest that LATS2 may play a role in AR-mediated transcription and contribute to the development of prostate cancer.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR
Coregulators:   LATS2
Ligands:   Dihydrotestosterone  |  R1881






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society